Edimer Pharmaceuticals Secures $18,000,000 Series B Funding

  • Feed Type
  • Date
    7/30/2013
  • Company Name
    Edimer Pharmaceuticals
  • Mailing Address
    55 Cambridge Parkway Cambridge, MA 02142
  • Company Description
    Edimer Pharmaceuticals is dedicated to developing EDI200 as a treatment for X-linked Hypohydrotic Ectodermal Dysplasia (XLHED). XLHED is a rare, orphan disease that causes a range of symptoms including lack of sweat glands, poor temperature control, respiratory problems, and hair and tooth malformations.
  • Website
    http://www.edimerpharma.com
  • Transaction Type
    Venture Equity
  • Transaction Amount
    $18,000,000
  • Transaction Round
    Series B
  • Proceeds Purposes
    Edimer plans to use the proceeds from this financing to advance the later stage clinical development of EDI200, the company’s novel, proprietary, recombinant protein being developed for the treatment of XLHED.
  • M&A Terms
  • Venture Investor
    New Enterprise Associates
  • Venture Investor
    Sanofi-Genzyme BioVentures
  • Venture Investor
    Third Rock Ventures
  • Venture Investor
    VI Partners

By posting a comment, you agree to our terms and conditions.